GeoVax Labs (GOVX)

• Market cap: $3.56M
• 1 day: -2.38%
• 5 days: -25.9%
• 1 month: -3.91%
• 3 months: -22.15%
• 6 months: -88%
• Year to date: -76.25%
• 1 year: -94.58%
• 5 years: -99.94%
• 10 years: -99.89%
• Sector: Healthcare
• Industry: Biotechnology

About: Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

Employees: 19